Verve Therapeutics, Inc. (VERV)
Automate Your Wheel Strategy on VERV
With Tiblio's Option Bot, you can configure your own wheel strategy including VERV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VERV
- Rev/Share 0.6862
- Book/Share 5.4506
- PB 2.0402
- Debt/Equity 0.145
- CurrentRatio 9.843
- ROIC -0.3643
- MktCap 991272384.0
- FreeCF/Share -1.6919
- PFCF -6.7442
- PE -5.3371
- Debt/Assets 0.1118
- DivYield 0
- ROE -0.3582
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | VERV | Cantor Fitzgerald | Neutral | Overweight | -- | -- | April 15, 2025 |
News
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Verve Therapeutics, Inc. (NASDAQ: VERV ) related to its sale to Eli Lilly. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share …
Read More
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Read More
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.
Read More
VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders
Published: June 17, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones. Halper Sadeh encourag.
Read More
Biotech Stock Surging on Billion-Dollar Buyout
Published: June 17, 2025 by: Schaeffers Research
Sentiment: Positive
Biotech stock Verve Therapeutics Inc (NASDAQ:VERV) is up 75.3% to trade at $10.99 at last check amid news that peer Eli Lilly (LLY) will buy the company for $10.50 per share, or roughly $1.3 billion.
Read More
What Makes Verve Therapeutics (VERV) a New Buy Stock
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Verve Therapeutics (VERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Verve Therapeutics (VERV) is looking like an interesting pick, as it just reached a key level of support. VERV recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Read More
Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 367.9% upside potential for Verve Therapeutics (VERV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Read More
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Verve Therapeutics (VERV) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.59 per share a year ago.
Read More
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'
Published: April 16, 2025 by: Seeking Alpha
Sentiment: Positive
VERV's VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102's development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV's pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly.
Read More
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.
Read More
Why Verve Therapeutics Is Skyrocketing Today
Published: April 15, 2025 by: The Motley Fool
Sentiment: Positive
Verve Therapeutics (VERV 22.57%) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m.
Read More
Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose
Published: April 14, 2025 by: Benzinga
Sentiment: Positive
Verve Therapeutics Inc VERV on Monday released initial data from the Heart-2 Phase 1b trial of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD), which requires reducing low-density lipoprotein cholesterol (LDL-C) levels in the blood.
Read More
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for VERVE-102 for the treatment of patients living with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). VERVE-102 is a novel, investigational in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood low-density lipoprotein cholesterol (LDL-C).
Read More
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025
Read More
About Verve Therapeutics, Inc. (VERV)
- IPO Date 2021-06-17
- Website https://www.vervetx.com
- Industry Biotechnology
- CEO Dr. Sekar Kathiresan M.D.
- Employees 274